tp53bp1 antibody  (Abnova)

Journal: Journal of medicinal chemistry

Article Title: Discovery of Potent Isoquinolinequinone N -Oxides to Overcome Cancer Multidrug Resistance.

doi: 10.1021/acs.jmedchem.4c00705

Figure Lengend Snippet: Figure 10. Effect of compound 25 on the NCI-H460 cellular expression of proteins involved in proliferation, cell death and DNA damage, analyzed by Western Blotting. (A) Representative blots of TP53BP1, PARP-1, cyclin D1, p21, cyclin E, p-histone H2A.X, p53, and procaspase-3, after cells treatment for 48 h with medium, DMSO (vehicle), doxorubicin (positive control), GI50 concentration (0.35 μM), or 2 × GI50 concentration (0.7 μM) of compound 25. V1, % of vehicle used at the GI50 concentration of compound; V2, % of vehicle used at 2 × GI50 concentration of compound. Doxo: doxorubicin at 50 nM. (B) Graphical representation of the expression of proteins analyzed. β-actin was used as loading control. Results are the mean ± SEM from 3 independent experiments. * p ≤0.05, ** p ≤0.01 when comparing DMSO vs compound treatment.

Article Snippet: The membranes were incubated for 90 min at RT with the following primary antibodies: caspase-3 (1:200; sc-56053), cyclin D1 (1:200; sc-8396), cyclin E (1:100; sc-377100), p21 (1:200; sc-6246), p53 (1:200; sc-126), PARP-1 (1:200; sc-8007), p-Histone H2A.X (1:200; sc-517348), TP53BP1 (1:100; sc-515841), and β-actin (1:200; sc13118) from Santa Cruz Biotechnology, Dallas, Texas, USA.

Techniques: Expressing, Western Blot, Positive Control, Concentration Assay, Control